SCHEMBL18683054

SCHEMBL18683054

CC(C)(C)OC(=O)N[C@@](C)(CCO)c1cc(Br)ccc1F

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 14/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
RECQL P46063 1/20 0.37
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
USP28 Q96RU2 1/20 0.35
USP25 Q9UHP3 1/20 0.35
USP30 Q70CQ3 1/20 0.35
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27945123 0.90 AAK1 (0.50) AAK1PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL253236 0.90 AAK1 (0.50) AAK1PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL244454 0.85 AAK1 (0.48) AAK1PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL18682936 0.85 AAK1 (0.45) AAK1PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL21677166 0.85 AAK1 (0.45) AAK1PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL15187901 0.84 AAK1 (0.47) AAK1PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL15839647 0.84 AAK1 (0.47) AAK1NPC1RAB9ASMN1; SMN2RECQL
SCHEMBL362462 0.84 AAK1 (0.47) AAK1PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL15187905 0.83 AAK1 (0.47) AAK1PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL16461442 0.82 AAK1 (0.46) AAK1PTGDR2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3353163-B1 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2020-02-05 EP disclosed
WO-2017050978-A1 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-03-30 WO disclosed